382 related articles for article (PubMed ID: 17548806)
1. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C
J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806
[TBL] [Abstract][Full Text] [Related]
2. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs.
Avbelj M; Horvat S; Jerala R
J Immunol; 2011 Sep; 187(5):2394-404. PubMed ID: 21804016
[TBL] [Abstract][Full Text] [Related]
3. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling.
Zhu Y; Li T; Song J; Liu C; Hu Y; Que L; Ha T; Kelley J; Chen Q; Li C; Li Y
Basic Res Cardiol; 2011 Sep; 106(5):787-99. PubMed ID: 21533832
[TBL] [Abstract][Full Text] [Related]
4. A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling.
Rao N; Nguyen S; Ngo K; Fung-Leung WP
Mol Cell Biol; 2005 Aug; 25(15):6521-32. PubMed ID: 16024789
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and in vitro activity of peptidomimetic inhibitors of myeloid differentiation factor 88.
Fantò N; Gallo G; Ciacci A; Semproni M; Vignola D; Quaglia M; Bombardi V; Mastroianni D; Zibella MP; Basile G; Sassano M; Ruggiero V; De Santis R; Carminati P
J Med Chem; 2008 Mar; 51(5):1189-202. PubMed ID: 18275134
[TBL] [Abstract][Full Text] [Related]
6. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation.
Ahmad R; Sylvester J; Zafarullah M
Cell Signal; 2007 Dec; 19(12):2549-57. PubMed ID: 17905570
[TBL] [Abstract][Full Text] [Related]
7. PKC-alpha controls MYD88-dependent TLR/IL-1R signaling and cytokine production in mouse and human dendritic cells.
Langlet C; Springael C; Johnson J; Thomas S; Flamand V; Leitges M; Goldman M; Aksoy E; Willems F
Eur J Immunol; 2010 Feb; 40(2):505-15. PubMed ID: 19950169
[TBL] [Abstract][Full Text] [Related]
8. The TIR/BB-loop mimetic AS-1 protects the myocardium from ischaemia/reperfusion injury.
Cao Z; Hu Y; Wu W; Ha T; Kelley J; Deng C; Chen Q; Li C; Li J; Li Y
Cardiovasc Res; 2009 Dec; 84(3):442-51. PubMed ID: 19586942
[TBL] [Abstract][Full Text] [Related]
9. MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.
Shiratori E; Itoh M; Tohda S
Anticancer Res; 2017 Nov; 37(11):6203-6209. PubMed ID: 29061802
[TBL] [Abstract][Full Text] [Related]
10. Constitutive association of MyD88 to IRAK in HTLV-I-transformed T cells.
Mizobe T; Tsukada J; Higashi T; Mouri F; Matsuura A; Tanikawa R; Minami Y; Yoshida Y; Tanaka Y
Exp Hematol; 2007 Dec; 35(12):1812-22. PubMed ID: 17920759
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.
Loiarro M; Volpe E; Ruggiero V; Gallo G; Furlan R; Maiorino C; Battistini L; Sette C
J Biol Chem; 2013 Oct; 288(42):30210-30222. PubMed ID: 24019529
[TBL] [Abstract][Full Text] [Related]
12. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
13. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
Li X
Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Inflammatory Cytokine Release from IL-1β and LPS-Stimulated PBMC Orchestrated by ST2825, a MyD88 Dimerisation Inhibitor.
Ramírez-Pérez S; Hernández-Palma LA; Oregon-Romero E; Anaya-Macías BU; García-Arellano S; González-Estevez G; Muñoz-Valle JF
Molecules; 2020 Sep; 25(18):. PubMed ID: 32967164
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse.
Van Tassell BW; Seropian IM; Toldo S; Salloum FN; Smithson L; Varma A; Hoke NN; Gelwix C; Chau V; Abbate A
J Cardiovasc Pharmacol; 2010 Apr; 55(4):385-90. PubMed ID: 20125030
[TBL] [Abstract][Full Text] [Related]
16. Roles of lipoxin A4 receptor activation and anti-interleukin-1β antibody on the toll-like receptor 2/mycloid differentiation factor 88/nuclear factor-κB pathway in airway inflammation induced by ovalbumin.
Kong X; Wu SH; Zhang L; Chen XQ
Mol Med Rep; 2015 Jul; 12(1):895-904. PubMed ID: 25760938
[TBL] [Abstract][Full Text] [Related]
17. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.
Fitzgerald KA; Palsson-McDermott EM; Bowie AG; Jefferies CA; Mansell AS; Brady G; Brint E; Dunne A; Gray P; Harte MT; McMurray D; Smith DE; Sims JE; Bird TA; O'Neill LA
Nature; 2001 Sep; 413(6851):78-83. PubMed ID: 11544529
[TBL] [Abstract][Full Text] [Related]
18. Cystatin cures visceral leishmaniasis by NF-κB-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway.
Kar S; Ukil A; Das PK
Eur J Immunol; 2011 Jan; 41(1):116-27. PubMed ID: 21182083
[TBL] [Abstract][Full Text] [Related]
19. Brazilin selectively disrupts proximal IL-1 receptor signaling complex formation by targeting an IKK-upstream signaling components.
Jeon J; Lee JH; Park KA; Byun HS; Lee H; Lee Y; Zhang T; Kang K; Seok JH; Kwon HJ; Han MD; Kang SW; Hong JH; Hur GM
Biochem Pharmacol; 2014 Jun; 89(4):515-25. PubMed ID: 24735611
[TBL] [Abstract][Full Text] [Related]
20. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.
Horng T; Barton GM; Flavell RA; Medzhitov R
Nature; 2002 Nov; 420(6913):329-33. PubMed ID: 12447442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
